|
注册号: Registration number: |
ChiCTR-DDD-17012163 |
|
最近更新日期: Date of Last Refreshed on: |
2017-07-27 17:10:37 |
|
注册时间: Date of Registration: |
2017-07-27 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
二代测序技术在感染病精准诊断中的应用及推广 |
|
Public title: |
Application of NGS Technique in Precise Diagnosis of Infectious Diseases |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
二代测序技术在感染病精准诊断中的应用及推广 |
|
Scientific title: |
Application of NGS Technique in Precise Diagnosis of Infectious Diseases |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
艾静文 |
研究负责人: |
张文宏 |
|
Applicant: |
Ai Jingwen |
Study leader: |
Zhang Wenhong |
|
申请注册联系人电话: Applicant telephone: |
+86 13764990804 |
研究负责人电话:
Study leader's |
+86 13801844344 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
jingwenai1990@126.com |
研究负责人电子邮件: Study leader's E-mail: |
zhangwenhong@fudan.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市乌鲁木齐中路12号复旦大学附属华山医院5号楼504室 |
研究负责人通讯地址: |
上海市乌鲁木齐中路12号复旦大学附属华山医院5号楼504室 |
|
Applicant address: |
12 Wulumuqi Middle Road, Shanghai, China |
Study leader's address: |
12 Wulumuqi Middle Road, Shanghai, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
复旦大学附属华山医院 |
||
|
Applicant's institution: |
Huashan Hospital affiliated to Fudan University |
||
|
研究负责人所在单位: |
复旦大学附属华山医院 |
||
|
Affiliation of the Leader: |
Huashan Hospital affiliated to Fudan University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2017-338 |
伦理委员会批件附件: Approved file of Ethical Committee: |
|
|
批准本研究的伦理委员会名称: |
复旦大学附属华山医院伦理审查委员会 |
||
|
Name of the ethic committee: |
Institutional Review Board of Huashan Hospital, Fudan University (HIRB) |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
1990-01-01 00:00:00 | ||
|
伦理委员会联系人: |
|
||
|
Contact Name of the ethic committee: |
|
||
|
伦理委员会联系地址: |
|
||
|
Contact Address of the ethic committee: |
|
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
复旦大学附属华山医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Huashan Hospital affiliated to Fudan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
复旦大学附属华山医院 |
||||||||||||||||||||||
|
Primary sponsor's address: |
12 Wulumuqi Middle Road, Shanghai, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
课题经费 |
||||||||||||||||||||||
|
Source(s) of funding: |
Project funding |
||||||||||||||||||||||
|
研究疾病: |
感染疾病 |
||||||||||||||||||||||
|
Target disease: |
Infectious Diseases |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
诊断试验 |
||||||||||||||||||||||
|
Study type: |
Diagnostic test |
||||||||||||||||||||||
|
研究所处阶段: |
诊断试验新技术临床试验 | ||||||||||||||||||||||
|
Study phase: |
Diagnostic New Technique Clincal Study |
||||||||||||||||||||||
|
研究设计: |
诊断试验诊断准确性 |
||||||||||||||||||||||
|
Study design: |
Diagnostic test for accuracy |
||||||||||||||||||||||
|
研究目的: |
本项目主要研究二代测序技术在感染病精准诊断中的价值、标准试验流程制定及推广。 明确病原体种类及其耐药性是感染病治疗中最为重要的环节之一,能够帮组临床医生开展合理用药,有效治疗。但由于能够感染人类的细菌、真菌、病毒种类众多,传统的检测手段如细菌培养、PCR扩增以及免疫反应等,检测通量较低,一般一次检测仅能针对少数几种病原体,为了明确诊断结果,通常需要进行多次检测,耗时较长;二代测序技术是最近发展起来的一种快速、高通量的获得核酸序列信息的技术,而临床常见病原体均含有核酸,且能够通过核酸序列明确病原体的种类及耐药情况,这使得二代测序技术有可能成为一种快速的、普适的感染病诊断方法。 自2014年在新英格兰医学杂志上首次报道一例用二代测序技术诊断钩端螺旋体感染的病例以来,其诊断价值迅速被认可。我们前期已采用二代测序技术对近两百例临床样本进行了检测,结果与临床情高度符合;二代测序技术对各个步骤的操作均有较高要求,为了使其能够更好的服务于临床,本项目拟在前期工作的基础上进一步优化检测流程,扩大样本数量,与其它医院组建多中心临床试验,全面评估二代测序技术在呼吸道感染、血流感染、中枢神经系统感染等各种感染病中的诊断价值;制定检测流程中各个环节的标准操作,如标本采集、核酸提取、建库流程以及报告解读等;并以此标准操作流程,将二代测序技术诊断感染性疾病推广到更多医院。 通过本项目的实施将对感染病的诊断方法带来重大改变,显著提升我国的感染病诊断能力,达到世界先进水平。 |
||||||||||||||||||||||
|
Objectives of Study: |
This project mainly studies the value of the next generation sequencing technology in the diagnosis of infectious diseases. Diagnosis of pathogen is one of the most important factors for clinicians to carry out rational use of drugs, effective treatment. However, the traditional detection methods such as bacterial culture, PCR amplification and immune response, detection flux has limited sensitivity. The next-generation sequencing is a recently developed high-throughput technology to obtain nucleic acid sequence information, which makes the next-generation of sequencing technology may become a fast, universal infection diagnosis method. The diagnostic value has been rapidly recognized since the first case publish in the New England Journal of Medicine, which reported a case of diagnosis of leptospirosis with next-generation sequencing technique. The project is based on the preliminary work to further optimize the detection process and expand the number of samples, in order to achieve a comprehensive assessment of next-generation sequencing technology in respiratory infections, bloodstream infections, central nervous system infections and etc. Through the implementation of this project, we hope to enhance the diagnosis of infectious diseases in China into the world advanced level. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
排除标准: |
||||||||||||||||||||||
|
Exclusion criteria: |
Exclusion criteria: |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2017-08-01 00:00:00至 To 2020-08-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2017-08-01 00:00:00 至 To 2020-08-01 00:00:00 |
|
诊断试验: Diagnostic Tests: |
|
||||||||||||||||||||||||||||
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
本课题非随机队列研究 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
This is a non-random cohort study |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
试验完成后6个月内,采用中国知网平台,以论文公开。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
6 months after the completion of the test, we will use of China Knowledge Network platform to publish the paper. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集以病历电子记录表采集,管理以电子病历管理系统综合管理。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
The study will use electronic medical records to collect data, and management system is used to organize all the case records |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |